it may be time to explore a different path. The LATITUDE Psoriasis Studies are evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.
What if you could potentially impact the 125 million people worldwide (2–3% of the entire population) with psoriasis?1 Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies.
Participation in clinical research for psoriasis has an impact on 125 million people worldwide (2-3% of the entire population) with psoriasis.1 Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies.
Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies. This program is evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.
The investigational treatment works by helping to control inflammatory signals known to contribute to the buildup of plaque psoriasis. Participants will receive the investigational treatment, Otezla®* (an approved oral treatment for moderate to severe plaque psoriasis), or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.
Participants originally assigned to placebo who still have active disease during the study will have the opportunity to switch to the investigational treatment. All study treatments will be given as oral pills.
Neither participants nor the study staff will know if participants are receiving the investigational treatment, the approved oral treatment, or a placebo. Participants will attend up to 20 scheduled study visits over the course of about a year.
We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.
For more detailed information on the cookies we use, please check our Privacy Policy.
By continuing to access this website, you are giving us consent to collect cookies.